Daniel Herchenhorn

1.7k total citations
47 papers, 575 citations indexed

About

Daniel Herchenhorn is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Daniel Herchenhorn has authored 47 papers receiving a total of 575 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 12 papers in Surgery. Recurrent topics in Daniel Herchenhorn's work include Prostate Cancer Treatment and Research (15 papers), Head and Neck Cancer Studies (11 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Daniel Herchenhorn is often cited by papers focused on Prostate Cancer Treatment and Research (15 papers), Head and Neck Cancer Studies (11 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Daniel Herchenhorn collaborates with scholars based in Brazil, United States and Italy. Daniel Herchenhorn's co-authors include Carlos Gil Ferreira, Fernando Luiz Dias, I. A. Small, Célia M. Viégas, Carlos M. Araújo, Héliton Spíndola Antunes, Òren Smaletz, Fernando Cotait Maluf, Renata Erthal Knust and Renato Martins and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Daniel Herchenhorn

41 papers receiving 565 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Herchenhorn Brazil 14 395 205 191 178 97 47 575
Samir Abdallah Hanna Brazil 12 202 0.5× 134 0.7× 146 0.8× 150 0.8× 156 1.6× 70 627
P. Sebastian India 14 178 0.5× 232 1.1× 68 0.4× 208 1.2× 210 2.2× 29 699
João Luís Fernandes da Silva Brazil 11 188 0.5× 110 0.5× 97 0.5× 173 1.0× 112 1.2× 28 481
Kuniaki Katsui Japan 17 452 1.1× 251 1.2× 129 0.7× 85 0.5× 185 1.9× 79 736
Carlo Furlan Italy 13 252 0.6× 180 0.9× 134 0.7× 88 0.5× 98 1.0× 29 515
Loredana Costa Italy 11 202 0.5× 176 0.9× 39 0.2× 215 1.2× 124 1.3× 29 496
Richard Lizambri United States 10 320 0.8× 179 0.9× 56 0.3× 219 1.2× 50 0.5× 16 521
Hiroki Mitani Japan 15 147 0.4× 321 1.6× 40 0.2× 226 1.3× 470 4.8× 85 800
Beth Eaby‐Sandy United States 7 332 0.8× 664 3.2× 164 0.9× 55 0.3× 103 1.1× 12 946
A. Richetti Switzerland 13 253 0.6× 178 0.9× 120 0.6× 136 0.8× 186 1.9× 40 569

Countries citing papers authored by Daniel Herchenhorn

Since Specialization
Citations

This map shows the geographic impact of Daniel Herchenhorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Herchenhorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Herchenhorn more than expected).

Fields of papers citing papers by Daniel Herchenhorn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Herchenhorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Herchenhorn. The network helps show where Daniel Herchenhorn may publish in the future.

Co-authorship network of co-authors of Daniel Herchenhorn

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Herchenhorn. A scholar is included among the top collaborators of Daniel Herchenhorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Herchenhorn. Daniel Herchenhorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Silva, Viviane Aline Oliveira, et al.. (2025). Safety and effectiveness of immune checkpoint inhibitors in patients with preexisting autoimmune diseases: a systematic review. Frontiers in Immunology. 16. 1712632–1712632.
2.
Riviere, Paul, Margaret Meagher, Tyler J. Nelson, et al.. (2025). Osteoporosis Amongst Testicular Cancer Survivors: Long Term Follow-Up of the Veterans Affairs Health System. Clinical Genitourinary Cancer. 23(3). 102332–102332.
3.
Monteiro, Fernando Sabino Marques, Denizar Vianna Araújo, Rana R. McKay, et al.. (2024). Surgical Castration as an Alternative to Improve Systemic Treatment for Advanced Prostate Cancer: A Window of Opportunity for Developing Countries. JCO Global Oncology. 10(10). e2400319–e2400319.
4.
Choi, Sharon H., Elizabeth Pan, Andrew Elliott, et al.. (2024). Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer. Molecular Cancer Research. 22(10). 920–931. 1 indexed citations
5.
6.
Shabaik, Ahmed, Ithaar Derweesh, Aditya Bagrodia, et al.. (2023). Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy. Clinical Genitourinary Cancer. 21(6). 660–668.e1. 4 indexed citations
7.
Jani, Chinmay, et al.. (2023). New drug approvals in prostate cancer and their effect on the treatment landscape.. PubMed. 21(6). 321–340. 2 indexed citations
8.
Dettino, Aldo Lourenço Abbade, Ariel Galapo Kann, Carlos Dzik, et al.. (2021). Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries. JCO Global Oncology. 7(7). 545–549. 1 indexed citations
9.
Herchenhorn, Daniel, et al.. (2021). Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors – a single Brazilian center experience. Archives of Endocrinology and Metabolism. 65(4). 411–420. 6 indexed citations
10.
Herchenhorn, Daniel, et al.. (2021). Sequential therapies for advanced urothelial cancer: Hope meets new challenges. Critical Reviews in Oncology/Hematology. 160. 103248–103248. 1 indexed citations
11.
12.
Antunes, Héliton Spíndola, Gabriel Wajnberg, Daniel Herchenhorn, et al.. (2017). cDNA microarray analysis of human keratinocytes cells of patients submitted to chemoradiotherapy and oral photobiomodulation therapy: pilot study. Lasers in Medical Science. 33(1). 11–18. 13 indexed citations
13.
Vas, Jaya, Carlos H. Barrios, Daniel Herchenhorn, et al.. (2016). Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma. OncoTargets and Therapy. Volume 9. 5839–5845. 8 indexed citations
14.
Antunes, Héliton Spíndola, Daniel Herchenhorn, I. A. Small, et al.. (2015). Cost-effectiveness of low-level laser therapy (LLLT) in head and neck cancer patients receiving concurrent chemoradiation. Oral Oncology. 52. 85–90. 48 indexed citations
15.
Antunes, Héliton Spíndola, Daniel Herchenhorn, I. A. Small, et al.. (2013). Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation. Radiotherapy and Oncology. 109(2). 297–302. 96 indexed citations
16.
Linhares, Eduardo, et al.. (2011). Tumor estromal gastrointestinal: análise de 146 casos do centro de referência do Instituto Nacional do Câncer - INCA. SHILAP Revista de lepidopterología. 38(6). 398–406. 5 indexed citations
17.
Herchenhorn, Daniel, Fernando Luiz Dias, Célia M. Viégas, et al.. (2010). Phase I/II Study of Erlotinib Combined With Cisplatin and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology*Biology*Physics. 78(3). 696–702. 30 indexed citations
18.
Herchenhorn, Daniel, Fernando Luiz Dias, Carlos Gil Ferreira, et al.. (2008). Impact of Previous Tracheotomy as a Prognostic Factor in Patients with Locally Advanced Squamous Cell Carcinoma of the Larynx Submitted to Concomitant Chemotherapy and Radiation. ORL. 70(6). 381–388. 16 indexed citations
19.
Dienstmann, Rodrigo, Paula B. Andrade, Daniel Herchenhorn, et al.. (2008). XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy. Urologic Oncology Seminars and Original Investigations. 27(4). 382–390. 16 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samir Abdallah Hanna Breakdown of academic impact, for papers by P. Sebastian Breakdown of academic impact, for papers by João Luís Fernandes da Silva Breakdown of academic impact, for papers by Kuniaki Katsui Breakdown of academic impact, for papers by Carlo Furlan Breakdown of academic impact, for papers by Loredana Costa Breakdown of academic impact, for papers by Richard Lizambri Breakdown of academic impact, for papers by Hiroki Mitani Breakdown of academic impact, for papers by Beth Eaby‐Sandy Breakdown of academic impact, for papers by A. Richetti
Rankless by CCL
2026